Global Therapeutic Vaccines Market

Description

Overview

Therapeutic vaccination is one that is taken after infection to induce antiviral immunity and thereby change the course of the disease. It's ultimate goal is to change host immunity in order to eradicate disease and develop long-term memory.

The rapid advancement of nanobiotechnology has allowed for advancements in therapeutic cancer vaccinations. A therapeutic cancer vaccine's primary purpose is to elicit a cellular immune response, including the activation of killer T cells.

Market Dynamics: Drivers & Restraints

Increase in the prevalence of infectious diseases

The increase in infectious diseases has impacted the lives of a number of people. In order to prevent infections a number of new therapeutic vaccines have been introduced. The increase in innovations of therapeutic vaccines is expected to drive market growth.

For instance, according to the Centers for Disease Control (CDC), it is estimated that each year, up to 400 million people get infected with dengue. Approximately 100 million people get sick from infection, and 40,000 die from severe dengue.

Additionally, according to the report by World Health Organization (WHO), it is stated that researchers have estimated that every year, there are 1.3 to 4.0 million cases of cholera, and 21 000 to 143 000 deaths worldwide due to the infection. Cholera is considered an extremely serious disease that can cause severe acute watery diarrhea with severe dehydration.

The increase in the number of infectious diseases will increase the demand for therapeutic vaccines in order to treat infectious diseases by developing an immune response against the antigens present.

Restraint

Huge capital expenditure on vaccine development, the rising cost of research and development (R&D), biological and technical challenges associated with targeting more complex diseases, competition with better standards of care, the larger scale of clinical studies to prove safety and efficacy, and stringent regulations are the factors the market is expected to get hampered in the forecast period.

Segment Analysis

The global therapeutic vaccines market is segmented based on type, products, technology, distribution channel and region.

Cancer vaccines segment accounted for 38.3% of the market share

The ability to deliver all potential antigens to the immune system is the most essential advantage of cancer vaccines. Cancer vaccines, either allogeneic or autologous, can be created and delivered to patients using irradiation of whole cells or cell lysates.

Cancer vaccines segment has been holding a dominant segment in the therapeutic vaccines market due to the rise in the number of different cancers that can be treated through therapeutic vaccines. It is expected to continue throughout the forecast period. For instance, according to the American Society of Cancer, it is estimated that about 288,930 new cancer cases are to be diagnosed.

Additionally, it is estimated that about 82,290 new bladder cancer cases and 97,610 melanoma cases are to be diagnosed in the year 2023. The availability of tumor cell vaccines is expected to treat cancers. Thus, an increase in the incidence of cancer cases is expected to raise the growth of the segment.

Geographical Analysis

North America is expected to hold a significant position in the global therapeutic vaccines market share

North America is a dominant force in the global therapeutic vaccine market. The rising incidence of chronic infectious diseases, cancer, and Alzheimer's, are the factors that are driving the market growth. It is expected to continue throughout the forecast period.

According to Alzheimer's San Diego Organization, it is estimated that at least one person in America develops Alzheimer's every 67 seconds. It is estimated that nearly 500,000 new cases of Alzheimer's disease will be diagnosed in 2023.

Additionally, according to the American Society of Cancer, it is estimated that about 81,800 new cases of kidney cancer will be diagnosed. Thus, an increase in disease conditions is expected to increase the demand for therapeutic vaccines.

Also, the presence of key manufacturers, increasing investments by pharmaceutical companies for vaccine development in the region, proactive government initiatives, favorable subsidiaries, and a large patient pool are driving the market in North America.

COVID-19 Impact Analysis:

COVID-19 has impacted the growth of the market positively. There is a rise in the demand for therapeutic vaccines during this period. The increase in the cases of COVID-19 has increased the emergency and demand for the production of therapeutic vaccines which have the ability to produce antibodies against the virus.

Competitive Landscape

The leading companies with a significant market share in global therapeutic vaccines include: Elicio Therapeutics, Argos Therapeutics, CSL Limited, Johnson & Johnson, AstraZeneca Plc, Merck & Co., Inc., Eli Lilly and Company, Sanofi, Dynavax Technologies., and GSK Pharmaceuticals among others.

Key Developments

On January 24, 2023, the Serum Institute of India (SII) launched India's First Indigenously Made Cervical Cancer Vaccine 'CERVAVAC'.
On May 11, 2023, TechInvention Lifecare India in partnership with Eubiologics Co, South Korea, launched Euvichol-Plus, an oral cholera vaccine in India.

Why Purchase the Report?

To visualize the global therapeutic vaccines market segmentation based on type, products, technology, distribution channel and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of therapeutic vaccines market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global therapeutic vaccines market report would provide approximately 69 tables, 70 figures, and 183 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

Product Code: PH1542

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Products
3.3. Snippet by Technology
3.4. Snippet by Distribution Channel
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increase in the prevalence of infectious diseases
  - 4.1.1.2.
- 4.1.2. Restraints
  - 4.1.2.1. High investments in manufacturing
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. Antigen Vaccines *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Dendritic Cell Vaccine
7.4. DNA Vaccine
7.5. Tumor Cell Vaccines

8. By Products

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
- 8.1.2. Market Attractiveness Index, By Products
8.2. Autoimmune Disease Vaccine *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Addiction Vaccine
8.4. Cancer Vaccines
8.5. Neurological Disease Vaccine
8.6. Infectious Disease Vaccine
8.7. Others

9. By Technology

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.1.2. Market Attractiveness Index, By Technology
9.2. Autologous Vaccines *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Allogeneic Vaccines

10. By Distribution Channel

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. UK
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Products
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Elicio Therapeutics *
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Argos Therapeutics
13.3. CSL Limited
13.4. Johnson & Johnson
13.5. AstraZeneca Plc
13.6. Merck & Co., Inc.,
13.7. Eli Lilly and Company
13.8. Sanofi
13.9. Dynavax Technologies.
13.10. GSK Pharmaceuticals

LIST NOT EXHAUSTIVE.

14. Appendix

14.1. About Us and Services
14.2. Contact Us

Global Therapeutic Vaccines Market - 2023 -2030